In 2023, Zhangzhou Pientzehuang Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Zhangzhou Pientzehuang Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 |
|---|---|
Total Scope 1 | 2,300.93a |
Total Scope 2 | |
Unspecified Calculation Method | 7,433.3a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.6258a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Zhangzhou Pientzehuang Pharmaceutical amounted to 9,734.23 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2023, the total Scope 1 emissions of Zhangzhou Pientzehuang Pharmaceutical were 2,300.93 metric tons of CO₂ equivalent (tCO₂e).a
In 2023, Zhangzhou Pientzehuang Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 7,433.3 tCO₂e without specifying the calculation method.a
In 2023, Zhangzhou Pientzehuang Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Zhangzhou Pientzehuang Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 2,300.93 tCO₂e and total revenues of USD 1,415 millions. This translates into an emissions intensity of 1.63 tCO₂e per millions USD.a
In 2023, Zhangzhou Pientzehuang Pharmaceutical reported a Scope 1 emissions intensity of 1.63 tCO₂e per millions USD. Compared to the peer group median of 6.86, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2023, Zhangzhou Pientzehuang Pharmaceutical ranked 1 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Zhangzhou Pientzehuang Pharmaceutical among the top performers, with one of the lowest emissions intensities relative to peers.a